期刊文献+

二甲双胍在大鼠体内的药动学和组织分布 被引量:9

Pharmacokinetics and tissues distribution of metformin in rats
下载PDF
导出
摘要 目的研究二甲双胍在大鼠体内的药动学和组织分布。方法大鼠腹腔注射二甲双胍(100 mg·kg^(-1))并在0、10、20、30、60、120、240、480和720 min共9个时间点采集血样(大鼠共3只)和各组织样品(大鼠共27只,每个时间点3个),测定血浆和组织样品中的二甲双胍的浓度。结果AUC为(4 676±s 171)mg·min·L^(-1),CL为(21.4±0.8)mL·min^(-1)·kg^(-1),t(1/2)为(50±5)min,t_(max)为(20.0±1.0)min,c_(max)为(59±4)mg·L^(-1):给药后10 min,所有的组织中都能检测到二甲双胍,给药后12 h,肝脏、肺、脾脏和大脑中已检测不到二甲双胍。结论二甲双弧的血药浓度-时间曲线符合一室模型,在体内叹收快,兮布广泛,清除迅速,且可能主要是由肾脏清除;二甲双胍能够进入大脑。 AIM To investigate the distribution and pharmacokinetic properties of metformin in rats. METHODS After a single administration (ip) of metformin with a dose of 100 mg·kg^-1, the plasma samples from the rats (n = 3) were taken at 0, 10, 20, 30, 60, 120, 240, 480, and 720 min for determination of the pharmacokinetic parameters of metformin in rat blood. The various organ samples were also taken from another group of animals (n = 27, 3 rats per time point) for the distribution study of the drug. RESULTS The main pharmacokinetic parameters were as follow: A UC (4 676 + s 171 ) mg·min·L^-1, CL (21.4 ± 0.8) mL· min^-1·kg^-1, t1/2 (50 ± 5) min, tmax (20.0 ± 1.0) min, cmax (59 ± 4) mg·L^-1. Metformin were detected in all tissue samples 10 min after administration and could not be tested in liver, lung, spleen and brain 12 h after administration. CONCLUTION The plasma concentration-time curve of metformin revealed that the pharmacok- inetics of metformin in vivo fulfills the one-compartment model. The absorption, clearance with its diffuse distribution in vivo were rapid and the clearance appeared to be mainly via the kidney pathway. Metformin was readily permeable across the blood brain barrier.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2008年第3期202-206,共5页 Chinese Journal of New Drugs and Clinical Remedies
基金 上海市“浦江人才计划”资助项目(05PJ14044) 上海市“登山行动计划”重大资助项目(06DZ19002)
关键词 二甲双弧 药动学 组织分布 色谱 高压液相 metformin pharmacokinetics tissue distribution chromatography, high pressure liquid
  • 相关文献

参考文献21

  • 1SCHEEN AJ. Clinical pharmacokinetics of metformin[J]. Clin Pharmacokinet, 1996, 30(5): 359-371. 被引量:1
  • 2BORST SE, SNELLEN HG. Metformin, but not exercise training, increases insulin responsiveness in skeletal muscle of Sprague-Dawley rats[J]. Life Sci, 2001, 69(13): 1497-1507. 被引量:1
  • 3BAILEY CJ, TURNER RC. Metformin[J]. N Engl J Med, 1996,334(9): 574-579. 被引量:1
  • 4龚艳春,郭冀珍,陆俊茜,贾伟平.二甲双胍对155例肥胖高血压病病人血压及代谢的干预作用[J].中国新药与临床杂志,2005,24(4):280-283. 被引量:4
  • 5PETERSEN JS, DIBONA GF. Effects of central metformin administration on responses to air-jet stress and on arterial baroreflex function in spontaneously hypertensive rats [J]. J Hypertens, 1997, 15(3): 285-291. 被引量:1
  • 6PETERSEN JS, ANDERSEN D, MUNTZEL MS, et al. Intracerebroventricular metformin attenuates salt-induced hypertension in spontaneously hypertensive rats[J]. Am J Hypertens, 2001, 14(11 Pt 1): 1116-1122. 被引量:1
  • 7CHAU-VAN C, GAMBA M, SALVI R, et al. Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons[J]. Endocrinology, 2007, 148(2): 507- 511. 被引量:1
  • 8ROURU J , PESONEN U, KOULU M, et al. Anorectic effect of metformin in obese Zucker rats: lack of evidence for the involvement of neuropeptide Y[J]. Eur J Pharmacol, 1995, 273 (1-2): 99-106. 被引量:1
  • 9KAH HAY YUEN, KOK KHIANG PEH. Simple high-performance liquid chromatographic method for the determination of metformin in human plasma[J]. J Chromatogr B Biomed Sci Appl, 1998, 710(1-2) : 243-246. 被引量:1
  • 10CHENG CL, CHOU CH. Determination of metformin in human plasma by high-performance liquid chromatography with spectrophotometric detection[J]. J Chromatogr B Biomed Sci Appl, 2001, 762(1): 51-58. 被引量:1

二级参考文献29

  • 1王敬先 康晨霞.降血糖新药-盐酸二甲双胍.中国药理学通报,1996,12(4):3343-36. 被引量:11
  • 2DOLL S, PACCAUD F,BOVET P,et al. Body mass index , abdominal adiposity and blood pressure: consistency of their association across developing and developed countries[ J]. Int J Obes Relat Metab Disord, 2002,26( 1 ) :48-57. 被引量:1
  • 3SIVITZ WI. Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression [ J]. Postgrad Med,2001, 109(4) :55-59,63-64. 被引量:1
  • 4PARE A,DUMOUT M,LEMIENX I, et al. Is the relationship between adipose tissue and waist girth altered by weight loss in obese men? [J]. Obes Ras,2001,9(9) :526-534. 被引量:1
  • 5TANKOVA T. Current indications for metformin therapy[ J]. Rom J Intern Med, 2003,41 (3) :215-225. 被引量:1
  • 6DESPRES JP. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes [ J ]. Diabetes Metab,2003,29(4) :6S53-6S61. 被引量:1
  • 7IANNELLO S, CAMUTO M, CAVALERI A, et al. Effect of metfonnin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus[ J ]. Metabolism, 2004,53(2) :159-164. 被引量:1
  • 8KIRPICHNIKOV D, McFARLANE SI, SOWERS JR. Metformin :an update[J]. Ann Intern Med,2002,137( 1 ) :25-33. 被引量:1
  • 9MANZELLA D, GRELLA R, EPOSITO K, et al. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration [ J ]. Am J Hypertens,2004,17(3) :223-227. 被引量:1
  • 10MAKOLKIN Vl, PODZOLKOV VI, NAPALKOV DA. Assessment of efficacy of combined therapy with antihypertensive agents and biguanides in patients with metabolic syndrome[ J]. Kardiologiia,2004,44(10) :39-42. 被引量:1

共引文献52

同被引文献58

引证文献9

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部